全文获取类型
收费全文 | 3848篇 |
免费 | 316篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 164篇 |
妇产科学 | 112篇 |
基础医学 | 481篇 |
口腔科学 | 132篇 |
临床医学 | 420篇 |
内科学 | 838篇 |
皮肤病学 | 68篇 |
神经病学 | 221篇 |
特种医学 | 302篇 |
外科学 | 524篇 |
综合类 | 77篇 |
一般理论 | 1篇 |
预防医学 | 252篇 |
眼科学 | 37篇 |
药学 | 215篇 |
中国医学 | 5篇 |
肿瘤学 | 271篇 |
出版年
2021年 | 50篇 |
2020年 | 36篇 |
2019年 | 40篇 |
2018年 | 78篇 |
2017年 | 85篇 |
2016年 | 80篇 |
2015年 | 79篇 |
2014年 | 92篇 |
2013年 | 179篇 |
2012年 | 159篇 |
2011年 | 154篇 |
2010年 | 129篇 |
2009年 | 136篇 |
2008年 | 155篇 |
2007年 | 174篇 |
2006年 | 148篇 |
2005年 | 161篇 |
2004年 | 135篇 |
2003年 | 122篇 |
2002年 | 138篇 |
2001年 | 125篇 |
2000年 | 88篇 |
1999年 | 99篇 |
1998年 | 91篇 |
1997年 | 70篇 |
1996年 | 78篇 |
1995年 | 70篇 |
1994年 | 59篇 |
1993年 | 67篇 |
1992年 | 84篇 |
1991年 | 83篇 |
1990年 | 77篇 |
1989年 | 79篇 |
1988年 | 81篇 |
1987年 | 78篇 |
1986年 | 59篇 |
1985年 | 56篇 |
1984年 | 40篇 |
1983年 | 39篇 |
1981年 | 33篇 |
1980年 | 21篇 |
1979年 | 22篇 |
1978年 | 20篇 |
1977年 | 30篇 |
1976年 | 28篇 |
1975年 | 20篇 |
1974年 | 20篇 |
1973年 | 20篇 |
1971年 | 21篇 |
1969年 | 23篇 |
排序方式: 共有4176条查询结果,搜索用时 62 毫秒
1.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.2.
Timothy Fountaine Christopher R P Lind Andrew J J Law 《Journal of clinical neuroscience》2006,13(4):497-501
A 72-year-old man presented with a short duration of symptoms relating to a right fronto-parietal glioblastoma and a family history of children with brain tumours. Analysis of the patient's family tree revealed that out of seven children, he had a living son with anaplastic astrocytoma, a daughter who had died with a glioblastoma, and a son who had died with a histologically undiagnosed intrinsic brain tumour. One niece was also thought to have died from a brain tumour. All of the other affected family members had onset in their third or fourth decades. Tissue was only available from two of the affected individuals, precluding familial genetic analysis at this stage. There is no clinical evidence to support a diagnosis of a multiple cancer or neurocutaneous syndrome in this family. In view of what is known about the genetics of familial glioma, it is interesting to note the clinical evidence of both 'primary' glioblastoma and anaplastic astrocytoma in the same kindred. 相似文献
3.
M.B. McDermott A.C. Lind E.F. Marley L.P. Dehner 《Pediatric and developmental pathology》1998,1(4):300-308
Deep granuloma annulare (DGA) is one of several lesions of skin and superficial soft tissues whose histologic character is
a palisading granuloma with a small central focus of necrosis or necrobiosis. Unlike the other palisading necrobiotic lesions,
DGA has a predilection for children in the first 5 to 6 years of life. A painless subcutaneous nodule(s) in the lower anterior
tibial region or foot and the scalp, typically in the occiput, was the most common presenting feature in this study of 35
cases. Additional or recurrent lesions were reported in approximately 70% of cases with clinical follow-up. All lesions showed
the presence of necrobiosis; however, one of the characteristic features was the multinodular character of the predominantly
mononuclear cellular aggregates. The presence of vascular spaces at the periphery of the nodular profiles served as a clue
to the diagnosis of DGA. The palisading arrangement of the mononuclear cells was evident only in those foci with central necrobiosis.
A histiocytic disorder or fibrohistiocytic process was a common consideration in the differential diagnosis, especially in
those cases with less apparent foci of necrosis. Palisading histiocytes with prominent eosinophilic cytoplasm and some nuclear
atypism were problematic with regard to possible epithelioid sarcoma. Our study failed to identify any underlying or predisposing
factors in the development of DGA. Despite the fact that DGA is a well-documented lesion in children, it occurs sufficiently
infrequently that it is often not considered clinically when it presents as a subcutaneous mass or masses in a child. Its
recognition by the pathologist is especially important as the occurrence of additional lesions in a high proportion of children
can be anticipated without undue concern.
Received June 16, 1997; accepted October 28, 1997. 相似文献
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
6.
7.
8.
9.
臂丛神经根性损伤膈神经移位术对青壮年患者早期呼吸功能的影响 总被引:1,自引:1,他引:0
目的研究臂丛神经损伤膈神经移位术对青壮年患者早期呼吸功能的影响.方法对16例接受膈神经移位治疗的患者,在术前、术后(10 d)进行肺功能指标的比较,同时定期进行门诊随访,观察呼吸系统自觉症状程度.结果13例术后出现了不同程度的供氧不足症状,16例全部出现一侧膈肌抬高,术后第10天肺活量(VC)、肺活量预计值百分数(VC%)分别比术前减少37.98%和26.88%,两者差异有统计学意义(tvc=11.532、tvc%=0,P<0.01).其它项目如残气量(RV)较术前轻度下降,肺总量(TLC)下降值达到术前肺总量的36.49%,残气量/肺总量比值(RV/TLC%)较术前上升了4.75%,上述各指标的差值均有统计学意义.1 s用力呼气量/用力肺活量比值(FEV1/FVC)和术前比基本无改变,但其差值有统计学意义.膈神经移位右侧(10例)与左侧(6例)术前、术后肺活量比较差异有统计学意义.术后随访8个月~2年,所有患者均无明显呼吸困难和胸闷等症状.结论膈神经移位术后对青壮年患者肺容量有较大的丧失,肺通气功能减弱和小气道阻力增加,但其丧失程度在机体自身代偿耐受范围内,不会导致急剧发生的严重呼吸功能障碍.建议对右侧臂丛神经根性损伤的患者,术前进行严格的肺、心功能检查,避免发生较为严重的并发症. 相似文献
10.